( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	112

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

diseases per page:

Showing 1 to 10 of 112 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05470504 (ClinicalTrials.gov)	January 23, 2023	16/7/2022	Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance	Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance	Insulin Receptor Mutation;Partial Lipodystrophy	Drug: Pegvisomant	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Recruiting	18 Years	65 Years	All	25	Phase 2	United States
2	NCT05383456 (ClinicalTrials.gov)	April 18, 2022	8/4/2022	The Visceral Adiposity Measurement and Observation Study	The Visceral Adiposity Measurement and Observation Study	HIV;HIV-Infections;HIV-1-infection;HIV I Infection;HIV Lipodystrophy;HIV Infection Primary;HIV-Assoc ...	Diagnostic Test: Diagnostic Test;Drug: HIV Anti-retroviral Background Therapy	Theratechnologies	Dacima Consulting;Medpace, Inc.;Vanderbilt University Medical Center;Echosens	Recruiting	18 Years	N/A	All	400		United States
3	NCT05088460 (ClinicalTrials.gov)	February 28, 2022	12/10/2021	A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Pati ...	A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Tre ...	Familial Partial Lipodystrophy;Metabolic Abnormalities	Drug: REGN4461;Drug: Matching Placebo	Regeneron Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	40	Phase 2	United States;France;Spain;Turkey
4	NCT05164341 (ClinicalTrials.gov)	December 17, 2021	11/11/2021	Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects Wi ...	A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the S ...	Partial Lipodystrophy	Drug: metreleptin;Drug: Placebo	Amryt Pharma	NULL	Recruiting	12 Years	N/A	All	65	Phase 3	United States;Canada
5	NCT04710056 (ClinicalTrials.gov)	June 2021	13/1/2021	Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy ...		Generalized Lipodystrophy;Partial Lipodystrophy;Monogenic Obesity Due to LEP or LEPR Loss of Functio ...	Drug: REGN4461	Regeneron Pharmaceuticals	NULL	Available						NULL
6	NCT04860063 (ClinicalTrials.gov)	April 2021	17/4/2021	Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Th ...	Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Th ...	Metabolic Syndrome;HIV-1-infection;Glucose Intolerance;Dyslipidemias;Lipodystrophy;Lipoatrophy	Drug: Berberine;Drug: Placebo	Hospital Civil de Guadalajara	NULL	Not yet recruiting	18 Years	60 Years	All	40	Phase 3	NULL
7	NCT04903847 (ClinicalTrials.gov)	February 2, 2021	9/10/2020	Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Ten ...	Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compare ...	Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;Obesity	Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine/Lamivudine/Tenofovi ...	Thomas Benfield	NULL	Recruiting	18 Years	N/A	All	126	Phase 4	Denmark
8	NCT04904406 (ClinicalTrials.gov)	October 22, 2020	9/10/2020	Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-i ...	Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued ...	Hiv;HIV Infections;HIV Cardiomyopathy;Weight Change, Body;HIV Lipodystrophy;Cardiovascular Diseases	Drug: Dolutegravir / Lamivudine Oral Tablet	Thomas Benfield	NULL	Recruiting	18 Years	N/A	All	95	Phase 4	Denmark
9	NCT04340388 (ClinicalTrials.gov)	September 17, 2020	1/4/2020	Contribution of Dolutegravir to Obesity and Cardiovascular Disease	Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Person ...	HIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnor ...	Drug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIV	Augusta University	NULL	Recruiting	18 Years	100 Years	All	30	Phase 4	United States
10	NCT03900286 (ClinicalTrials.gov)	January 16, 2020	26/3/2019	Low Energy Diet and Familial Partial Lipodystrophy	Evaluating the Therapeutic Efficacy and Metabolic Impact of a Low Energy Diet (LED) in People With F ...	Lipodystrophy;Diabetes;Diet Modification	Dietary Supplement: Total Dietary Replacement	Cambridge University Hospitals NHS Foundation Trust	NULL	Recruiting	18 Years	99 Years	All	20	N/A	United Kingdom

First Previous1 2 3 4 5…12Next Last